Locations:
SearchNew imaging study is the first to use GE180 in this patient population to better understand the role of inflammation in disease pathology
Cleveland Clinic News Service | 216.444.0141
We’re available to shoot custom interviews & b-roll for media outlets upon request.
CCNS health and medical content is consumer-friendly, professional broadcast quality (available in HD), and available to media outlets each day.
images: 0
video: 0
audio: 0
text: 0
Las Vegas: The Cleveland Clinic Lou Ruvo Center for Brain Health has obtained the only Investigational New Drug (IND) to be issued by the Federal Drug Administration to test the GE180 ligand tracer, an experimental diagnostic imaging tool used to detect neuroinflammation, in the brains of those with Parkinson’s and Alzheimer’s disease.
Ligand tracers are used in radiology to help better depict protein interactions in living cells. Aaron Ritter, M.D., director of clinical trials at the Lou Ruvo Center for Brain Health, holds the IND for GE180 and serves as the principal investigator of a new positron emission tomography (PET) imaging study observing neuroinflammation in the brain.
The study’s goals are to better understand the link between inflammation and neurodegeneration, as well as determine if the tracer works in a new application: a patient population consisting of participants with normal cognitive function as well as Alzheimer’s and Parkinson’s disease. Currently, the Lou Ruvo Center for Brain Health is the first and only trial site testing GE180 in this patient population.
While inflammation is proven to play a role in both kidney and heart disease, the extent of its impact in brain disease is yet to be determined. Researchers are increasingly reporting that neuroinflammation — or over-activation of immune cells in the brain — may play an important role in pathology for diseases like Alzheimer’s and Parkinson’s, but more research is warranted.
“We do know there is some connection between inflammation and neurodegenerative disease, but we have yet to confirm what that is, and until now, it’s been hard to quantify in a living brain. The GE180 tracer is an exciting opportunity to contribute to the science of brain disease in ways that have not previously been studied,” said Dr. Ritter. “If we can confirm that inflammation plays a role in dementia, this could lead to new treatments that specifically target cognitive decline.”
The imaging study is an observational sub-study of the Lou Ruvo Center for Brain Health’s Center of Biomedical Research of Excellence (COBRE) grant, which aims to understand the similarities between Parkinson’s and Alzheimer’s disease. The two-year trial will use the GE180 tracer in conjunction with PET scans to detect neuroinflammation in the brains of 70 participants. The COBRE grant is funded by an Institutional Development Award (IDeA) P20GM109025 from the National Institutes of Health.
For additional information about the Cleveland Clinic Lou Ruvo Center for Brain Health, visit ClevelandClinic.org/Nevada.
About Cleveland Clinic
Cleveland Clinic is a nonprofit multispecialty academic medical center that integrates clinical and hospital care with research and education. Located in Cleveland, Ohio, it was founded in 1921 by four renowned physicians with a vision of providing outstanding patient care based upon the principles of cooperation, compassion and innovation. Cleveland Clinic has pioneered many medical breakthroughs, including coronary artery bypass surgery and the first face transplant in the United States. U.S. News & World Report consistently names Cleveland Clinic as one of the nation’s best hospitals in its annual “America’s Best Hospitals” survey. Among Cleveland Clinic’s 52,000 employees are more than 3,600 full-time salaried physicians and researchers and 14,000 nurses, representing 140 medical specialties and subspecialties. Cleveland Clinic’s health system includes a 165-acre main campus near downtown Cleveland, 11 regional hospitals, more than 150 northern Ohio outpatient locations – including 18 full-service family health centers and three health and wellness centers – and locations in Weston, Fla.; Las Vegas, Nev.; Toronto, Canada; Abu Dhabi, UAE; and London, England. In 2017, there were 7.6 million outpatient visits, 229,000 hospital admissions and 207,000 surgical cases throughout Cleveland Clinic’s health system. Patients came for treatment from every state and 185 countries. Visit us at clevelandclinic.org. Follow us at twitter.com/ClevelandClinic. News and resources available at newsroom.clevelandclinic.org.
About Cleveland Clinic Lou Ruvo Center for Brain Health
Cleveland Clinic Lou Ruvo Center for Brain Health provides expert diagnosis and treatment for individuals and families living with Alzheimer’s, Parkinson’s and Huntington’s diseases; multiple sclerosis; frontotemporal dementia and related disorders; and multiple system atrophy. The center offers a continuum of care with no-cost opportunities for the community to participate in education and research, including disease prevention studies and clinical trials of promising new medications. An integrated entity, Keep Memory Alive, raises funds exclusively in support of the Lou Ruvo Center for Brain Health in Las Vegas, Nevada. For more information, visit http://www.clevelandclinic.org/brainhealth and http://www.keepmemoryalive.org.
Editor’s Note: Cleveland Clinic News Service is available to provide broadcast-quality interviews and B-roll upon request.
